Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-11 of 11 for your search:
Cancer Type:
Lung cancer, non-small cell
Trial Type:
Prevention
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Selenium in Preventing Tumor Growth in Patients With Previously Resected Stage I Non-small Cell Lung Cancer
Phase:
Phase III
Type:
Prevention
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
ECOG-5597
, CAN-NCIC-BR16, CALGB-79803, NCCTG-E5597, SWOG-E5597, NCI-P00-0176, NCT00008385, BR16
2.
Iloprost in Preventing Lung Cancer in Patients at High Risk for This Disease
Phase:
Phase II
Type:
Prevention
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
UCHSC-01279
, NCT00084409
3.
Green Tea or Polyphenon E in Preventing Lung Cancer in Former Smokers With Chronic Obstructive Pulmonary Disease
Phase:
Phase II
Type:
Biomarker/Laboratory analysis, Prevention
Status:
Active
Age:
40 to 80
Sponsor:
NCI
Protocol IDs:
UARIZ-HSC-0353
, U01-CA-101204, NCT00363805
4.
Sulindac in Preventing Lung Cancer in Current or Former Smokers With Bronchial Dysplasia
Phase:
Phase II
Type:
Biomarker/Laboratory analysis, Prevention
Status:
Active
Age:
40 to 79
Sponsor:
NCI
Protocol IDs:
MAYO-03-1-02
, MAY03-1-02, NCT00368927
5.
Enzastaurin in Preventing Non-Small Cell Lung Cancer in Former Smokers
Phase:
Phase II
Type:
Biomarker/Laboratory analysis, Prevention
Status:
Active
Age:
45 and over
Sponsor:
NCI, Pharmaceutical / Industry
Protocol IDs:
MCC-14787
, H6Q-MC-S009, MCC-104545, LILLY-H6Q-MC-S009A, U01-CA-101222, NCT00387816
6.
A Trial of Placebo Versus Enzastaurin for Lung Cancer Prevention in Former Smokers
Phase:
Phase II
Type:
Prevention
Status:
Active
Age:
45 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
10723
, H6Q-MC-S009, NCT00414960
7.
Green Tea Extract in Treating Current or Former Smokers With Bronchial Dysplasia
Phase:
Phase II
Type:
Biomarker/Laboratory analysis, Prevention
Status:
Active
Age:
45 to 74
Sponsor:
NCI
Protocol IDs:
BCCA-H07-02401
, H07-02401, NCT00611650
8.
Inositol in Preventing Lung Cancer in Current or Former Smokers With Bronchial Dysplasia
Phase:
Phase II
Type:
Biomarker/Laboratory analysis, Prevention
Status:
Active
Age:
45 to 79
Sponsor:
NCI
Protocol IDs:
MAYO-MAY06-8-01
, MAY06-8-01, NCT00783705
9.
Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking
Phase:
No phase specified
Type:
Behavioral study, Biomarker/Laboratory analysis, Educational/Counseling/Training, Prevention
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
KUMC-HSC-10332
, 10332, KUMC-070313, NCT00666978
10.
Phenethyl Isothiocyanate in Preventing Lung Cancer in Smokers
Phase:
No phase specified
Type:
Biomarker/Laboratory analysis, Prevention
Status:
Approved-not yet active
Age:
21 to 70
Sponsor:
NCI
Protocol IDs:
UMN-2007NT127
, PEITC, NCT00691132
11.
Varenicline or Nicotine Patch and Nicotine Gum in Helping Smokers in a Methadone Treatment Program Stop Smoking
Phase:
No phase specified
Type:
Behavioral study, Prevention
Status:
Active
Age:
Over 18
Sponsor:
Other
Protocol IDs:
BUTLER-0807-004
, 0807-004, NCT00790569
Select All on Page
Help with Results
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute